Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: 4-HAD; 4-Hydroxyandrostenedione; 4-OHA; AT 0931; CGP 32349; CRC 8201; CRC-82/01; Formestane IM depot injection; Lentaron

Latest Information Update: 19 Jul 2010

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Class Androstenes; Antineoplastics; Ketosteroids; Small molecules
  • Mechanism of Action Aromatase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Market Withdrawal Breast cancer

Most Recent Events

  • 19 Jul 2010 Development discontinued for Breast cancer during 2001
  • 07 Mar 2003 A study has been added to the Cancer therapeutic trials section
  • 27 Apr 1999 Clinical data have been added to the therapeutic trials, pharmacodynamics and pharmacokinetics sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top